Hematology/Oncology

Top Story

The year of living dangerously

The year of living dangerously
HemOnc Today, February 10, 2016
Derek Raghavan, MD, PhD

The turmoil of December and early January has died down, and I have had time to think about the upcoming year, which seems to offer the possibility of being a year that could present some substantial hazards.

At a political level, one of the strangest U.S. presidential campaigns has been playing out in the press — hype and rhetoric seem to have dominated substantive discussion, and it is anyone’s guess as to which politicians will adopt specific policies on anything. Clearly outlandish statements command more airtime, and that tactic now seems to be commanding increased attention from several candidates.

Pharmacology ConsultPublication Exclusive

Biosimilars may expand drug access, reduce costs, but still much to learn

HemOnc Today, February 10, 2016
Jai N. Patel, PharmD
Cancer is the major indication for six of the 10 best-selling biological products.Meanwhile, the cost of cancer biologics in the United States has doubled from 2006 to…
Cover StoryPublication Exclusive

Gene therapy represents ‘new paradigm’ for treatment of hematologic disorders

HemOnc Today, February 10, 2016
Researchers in hematology have long believed that gene therapy may provide a pathway to more effectively treat chronic genetic hematologic disorders, with the potential…
Breaking News

Senate proposes new safety requirements for reusable devices

February 9, 2016
The Senate Committee on Health, Education, Labor and Pensions today favorably reported a bill requiring manufacturers of reusable medical devices like duodenoscopes to…
Breaking News

Legislators ask for national surveillance of neurological illnesses

February 9, 2016
The Senate health committee today recommended the establishment of a national surveillance system for neurological diseases.The objective of the “Advancing…
More News Headlines »
CME

Optimizing the Management of Metastatic Melanoma: Clinical Insights for Selecting First-line Therapy

This activity is supported by an independent educational grant from Merck & Co., Inc.

The incidence of melanoma is continuing to increase worldwide. In recent years, the treatment landscape for this…
More »
Video

VIDEO: Microsatellite instability predicts enhanced response to immunotherapy

February 4, 2016
More »
Featured
CME

The Patient with Myelofibrosis

No commercial support for this activity.

Myelofibrosis is caused by abnormal stem cells in the bone marrow that cause the uncontrolled production of mature…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan
morganatic-roan